Alessandra Nicoletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/840876/publications.pdf

Version: 2024-02-01

235 papers

7,847 citations

53660

h-index

45

69108

g-index

77

241 all docs

241 docs citations

times ranked

241

9237 citing authors

#	Article	IF	Citations
1	Burden of Parkinson's disease in Sicily: a health administrative database study. Neurological Sciences, 2022, 43, 1043-1046.	0.9	1
2	Pure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine. Neurological Sciences, 2022, 43, 1431-1433.	0.9	5
3	Executive functioning and serum lipid fractions in Parkinson's diseaseâ€"a possible sex-effect: the PACOS study. Journal of Neural Transmission, 2022, 129, 287-293.	1.4	7
4	Obsessive–compulsive personality disorder in rapid eye movement sleep behavior disorder. Scientific Reports, 2022, 12, 2401.	1.6	0
5	Relationship between risk and protective factors and clinical features of Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 80-85.	1.1	12
6	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic―neurology. European Journal of Neurology, 2021, 28, 1752-1758.	1.7	45
7	iNPH with parkinsonism: response to lumbar CSF drainage and ventriculoperitoneal shunting. Journal of Neurology, 2021, 268, 1254-1265.	1.8	10
8	Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study. Journal of Neurology, 2021, 268, 549-558.	1.8	28
9	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. Journal of Neurology, 2021, 268, 448-454.	1.8	16
10	Prevalence of idiopathic REM behavior disorder: a systematic review and meta-analysis. Sleep, 2021, 44, .	0.6	26
11	Usefulness of a smartphone application for the diagnosis of epilepsy: Validation study in high-income and rural low-income countries. Epilepsy and Behavior, 2021, 115, 107680.	0.9	7
12	Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study. Journal of Neurology, 2021, 268, 4258-4264.	1.8	4
13	Phonemic Verbal Fluency and Midbrain Atrophy in Progressive Supranuclear Palsy. Journal of Alzheimer's Disease, 2021, 80, 1669-1674.	1.2	5
14	Prevalence of isolated RBD in the city of Catania, Italy: a population-based study. Journal of Clinical Sleep Medicine, 2021, 17, 2241-2248.	1.4	11
15	The impact of COVID-19 pandemic on frail health systems of low- and middle-income countries: The case of epilepsy in the rural areas of the Bolivian Chaco. Epilepsy and Behavior, 2021, 118, 107917.	0.9	4
16	Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. Parkinsonism and Related Disorders, 2021, 87, 124-129.	1.1	13
17	Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. Parkinsonism and Related Disorders, 2021, 88, 40-45.	1.1	16
18	<i>Toxoplasma gondii</i> and multiple sclerosis: A systematic review and metaâ€analysis. European Journal of Neurology, 2021, 28, 4251-4257.	1.7	8

#	Article	IF	CITATIONS
19	Does an association between cigarette smoking and Parkinson's Disease-related psychosis exist? Insights from a large non-demented cohort. Journal of the Neurological Sciences, 2021, 427, 117509.	0.3	1
20	Neuroticism and Risk of Parkinson's Disease: A <scp>Metaâ€Analysis</scp> . Movement Disorders, 2021, 36, 2215-2215.	2.2	0
21	Incidence, survival and geoepidemiological analysis of meningiomas and glioblastomas in the province of Catania during the 2003–2016 period. Environmental Research, 2021, 200, 111286.	3.7	3
22	Impulsivity traits in eyelid myoclonia with absences. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 393-396.	0.9	0
23	Exome-wide association study of levodopa-induced dyskinesia in Parkinson's disease. Scientific Reports, 2021, 11, 19582.	1.6	3
24	Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS). Neurological Sciences, 2021, 42, 3723-3731.	0.9	18
25	Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort. Scientific Reports, 2021, 11, 867.	1.6	9
26	Influence of Drugs on Mild Cognitive Impairment in Parkinson's Disease: Evidence from the PACOS Study. Current Neuropharmacology, 2021, 20, .	1.4	1
27	Alprazolam for essential tremor. The Cochrane Library, 2020, 2020, CD009681.	1.5	3
28	Lack of association between Toxocara canis and multiple sclerosis: A population-based case–control study. Multiple Sclerosis Journal, 2020, 26, 258-259.	1.4	3
29	Lack of evidence for Toxocara infection in Italian myelitis patients. Neurological Sciences, 2020, 41, 239-241.	0.9	2
30	Specific Signatures of Serum miRNAs as Potential Biomarkers to Discriminate Clinically Similar Neurodegenerative and Vascular-Related Diseases. Cellular and Molecular Neurobiology, 2020, 40, 531-546.	1.7	99
31	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. Environmental Research, 2020, 182, 109022.	3.7	10
32	Retinal Thickness and Microvascular Pattern in Early Parkinson's Disease. Frontiers in Neurology, 2020, 11, 533375.	1.1	26
33	Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study. Journal of Neural Transmission, 2020, 127, 1589-1597.	1.4	11
34	"Begging the Questionâ€â€"Does Toxocara Infection/Exposure Associate with Multiple Sclerosis-Risk?. Pathogens, 2020, 9, 938.	1.2	9
35	Base-peak assessment of levodopa response and detection of fluctuating patients in Parkinson's disease. Neurological Sciences, 2020, 41, 3769-3773.	0.9	1
36	Parasomnias, sleep-related movement disorders and physiological sleep variants in focal epilepsy: A polysomnographic study. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 84-90.	0.9	9

#	Article	IF	Citations
37	A Measurement System to Monitor Postural Behavior: Strategy Assessment and Classification Rating. IEEE Transactions on Instrumentation and Measurement, 2020, 69, 8020-8031.	2.4	18
38	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. Movement Disorders Clinical Practice, 2020, 7, 920-929.	0.8	45
39	Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson's Disease and Progressive Supranuclear Palsy. Journal of Personalized Medicine, 2020, 10, 274.	1.1	24
40	Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. Frontiers in Psychiatry, 2020, 11, 590134.	1.3	46
41	Toxoplasma gondii and multiple sclerosis: a population-based case–control study. Scientific Reports, 2020, 10, 18855.	1.6	12
42	Asymmetry index of Blink Reflex Recovery Cycle differentiates Parkinson's disease from atypical Parkinsonian syndromes. Journal of Neurology, 2020, 267, 1859-1863.	1.8	6
43	Innovative IgG Biomarkers Based on Phage Display Microbial Amyloid Mimotope for State and Stage Diagnosis in Alzheimer's Disease. ACS Chemical Neuroscience, 2020, 11, 1013-1026.	1.7	17
44	Cutâ€off scores of blink reflex recovery cycle to differentiate atypical parkinsonisms. European Journal of Neurology, 2020, 27, e68.	1.7	2
45	Neurotoxocariasis. Advances in Parasitology, 2020, 109, 219-231.	1.4	14
46	Living near waterbodies as a proxy of cyanobacteria exposure and risk of amyotrophic lateral sclerosis: a population based case-control study. Environmental Research, 2020, 186, 109530.	3.7	18
47	Comic book-based educational program on epilepsy for high-school students: Results from a pilot study in the Gran Chaco region, Bolivia. Epilepsy and Behavior, 2020, 107, 107076.	0.9	14
48	Toxocara Brain Infection in Pigs is Not Associated with Visible Lesions on Brain Magnetic Resonance Imaging. American Journal of Tropical Medicine and Hygiene, 2020, 103, 273-275.	0.6	1
49	Seroprevalence of Toxocara canis in the city of Catania, Italy Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019031.	0.5	9
50	Validation of the Italian version of the PSP Quality of Life questionnaire. Neurological Sciences, 2019, 40, 2587-2594.	0.9	5
51	Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features. Neurological Sciences, 2019, 40, 2251-2263.	0.9	73
52	Cardiovascular autonomic function and MCI in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 55-58.	1.1	11
53	A sensing platform for postural behavior assessment. , 2019, , .		3
54	Hyperkinetic movement disorders in congenital disorders of glycosylation. European Journal of Neurology, 2019, 26, 1226-1234.	1.7	32

#	Article	IF	CITATIONS
55	Validation of the Italian version of carers' quality-of-life questionnaire for parkinsonism (PQoL) Tj ETQq1 1	0.784314 rgE	BT ₅ /Overlock
56	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. European Journal of Neurology, 2019, 26, e90-e91.	1.7	7
57	A screening questionnaire for generalized tonicâ€clonic seizures: Hospitalâ€based validation vs fieldâ€validation method. Epilepsia Open, 2019, 4, 339-343.	1.3	4
58	Eyelid myoclonia with absences: Electroclinical features and prognostic factors. Epilepsia, 2019, 60, 1104-1113.	2.6	27
59	Abnormal visual sensitivity in eyelid myoclonia with absences: Evidence from electrocortical connectivity and non-linear quantitative analysis of EEG signal. Seizure: the Journal of the British Epilepsy Association, 2019, 69, 118-124.	0.9	9
60	Mild Behavioral Impairment in Parkinson's Disease: Data from the Parkinson's Disease Cognitive Impairment Study (PACOS). Journal of Alzheimer's Disease, 2019, 68, 1603-1610.	1.2	12
61	Comment to: Trace elements in ALS patients and their relationships with clinical severity, by Oggiano R. etÂal Chemosphere, 2019, 233, 986-987.	4.2	1
62	Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study. Parkinsonism and Related Disorders, 2019, 64, 156-162.	1.1	18
63	Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease. Neurological Sciences, 2019, 40, 1271-1273.	0.9	5
64	Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study. Frontiers in Aging Neuroscience, 2019, 11, 21.	2 1.7	62
65	No Confirmed Cases of Taenia solium Taeniasis in a Group of Recently Arrived Sub-Saharan Migrants to Italy. Pathogens, 2019, 8, 296.	1.2	2
66	Knowledge, stigma, and quality of life in epilepsy: Results before and after a community-based epilepsy awareness program in rural Bolivia. Epilepsy and Behavior, 2019, 92, 90-97.	0.9	22
67	Complexity of electrocortical activity as potential biomarker in untreated Parkinson's disease. Journal of Neural Transmission, 2019, 126, 167-172.	1.4	8
68	Fluxgate Magnetometer and Performance for Measuring Iron Compounds. Lecture Notes in Electrical Engineering, 2019, , 509-517.	0.3	0
69	A Wearable Device to Support the Pull Test in Parkinson Disease. Lecture Notes in Electrical Engineering, 2019, , 251-260.	0.3	1
70	Mild cognitive impairment in Parkinson's disease: the Parkinson's disease cognitive study (PACOS). Journal of Neurology, 2018, 265, 1050-1058.	1.8	85
71	Personality and Parkinson's disease: A meta-analysis. Parkinsonism and Related Disorders, 2018, 51, 115.	1.1	0
72	Knowledge, attitudes, and practices towards epilepsy among general practitioners in rural Bolivia: Results before and after a training program on epilepsy. Epilepsy and Behavior, 2018, 83, 113-118.	0.9	13

#	Article	IF	CITATIONS
73	Forehead Tremor: A Clinical Presentation of Myasthenia Gravis?. Movement Disorders Clinical Practice, 2018, 5, 225-226.	0.8	1
74	Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis. Neurological Sciences, 2018, 39, 341-345.	0.9	7
75	Measurements of Iron Compound Content in the Brain Using a Flexible Core Fluxgate Magnetometer at Room Temperature. IEEE Transactions on Instrumentation and Measurement, 2018, 67, 971-980.	2.4	14
76	A Wearable Device to Support the Pull Test for Postural Instability Assessment in Parkinson's Disease. IEEE Transactions on Instrumentation and Measurement, 2018, 67, 218-228.	2.4	23
77	Treating People With Epilepsy in Rural Low-Income Countries Is Feasible. Observations and Reflections From a "Real Life Experience―After a Long Lasting Intervention in the Rural Chaco. Frontiers in Neurology, 2018, 9, 855.	1.1	6
78	Blink reflex recovery cycle to differentiate progressive supranuclear palsy from corticobasal syndrome. European Journal of Neurology, 2018, 25, 1100.	1.7	5
79	Temperament traits and executive functions in Parkinson's disease. Neuroscience Letters, 2018, 684, 25-28.	1.0	3
80	Clinical and Magnetic Resonance Imaging Findings of Neurotoxocariasis. Frontiers in Neurology, 2018, 9, 53.	1.1	33
81	Vascular Parkinsonism: Still Looking for a Diagnosis. Frontiers in Neurology, 2018, 9, 411.	1.1	12
82	Updated evidence of the association between toxocariasis and epilepsy: Systematic review and meta-analysis. PLoS Neglected Tropical Diseases, 2018, 12, e0006665.	1.3	51
83	A pressure measurement for pull test validation in postural instability assessment. , $2018, \ldots$		4
84	Frequency and Correlates of Subjective Memory Complaints in Parkinson's Disease with and without Mild Cognitive Impairment: Data from the Parkinson's Disease Cognitive Impairment Study. Journal of Alzheimer's Disease, 2018, 63, 1015-1024.	1.2	32
85	Knowledge and attitudes towards epilepsy among nonmedical health workers in rural Bolivia: Results after a long-term activity in the Chaco region. Epilepsy and Behavior, 2018, 85, 58-63.	0.9	12
86	The Parkinsonian Personality: More Than Just a "Trait― Frontiers in Neurology, 2018, 9, 1191.	1.1	16
87	A multisensor architecture for the assessment of postural sway in elderly and people with neurological disease. , 2017, , .		3
88	Topiramate for essential tremor. The Cochrane Library, 2017, 2017, CD009683.	1.5	7
89	Screening, diagnosis and management of human cysticercosis and <i>Taenia solium</i> taeniasis: technical recommendations by the <scp>COHEMI</scp> project study group. Tropical Medicine and International Health, 2017, 22, 881-894.	1.0	23
90	Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 24-31.	1.1	9

#	Article	IF	CITATIONS
91	Computer-assisted cognitive rehabilitation on freezing of gait in Parkinson's disease: A pilot study. Neuroscience Letters, 2017, 654, 38-41.	1.0	16
92	Quantitative estimation of motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 42, 34-39.	1.1	4
93	Geo-helminthiasis among migrants in Sicily: a possible focus for re-emerging neurocysticercosis in Europe. Neurological Sciences, 2017, 38, 1105-1107.	0.9	7
94	Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?. Parkinsonism and Related Disorders, 2017, 35, 69-74.	1.1	53
95	The relevance of gender in Parkinson's disease: a review. Journal of Neurology, 2017, 264, 1583-1607.	1.8	171
96	Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. Movement Disorders, 2017, 32, 1557-1565.	2.2	65
97	Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 1539-1546.	1.4	7
98	Zonisamide for essential tremor. The Cochrane Library, 2017, 2017, CD009684.	1.5	6
99	Vascular parkinsonism or idiopathic NPH? New insights from CSF pressure analysis. Neurological Sciences, 2017, 38, 2209-2212.	0.9	6
100	Head trauma and Parkinson's disease: results from an Italian case-control study. Neurological Sciences, 2017, 38, 1835-1839.	0.9	11
101	Metals and neurodegenerative diseases. A systematic review. Environmental Research, 2017, 159, 82-94.	3.7	178
102	Switching I-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease. Clinical Neuropharmacology, 2017, 40, 6-10.	0.2	3
103	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. European Radiology, 2017, 27, 2665-2675.	2.3	66
104	Wernicke encephalopathy and systemic sclerosis: rare association of rare conditions. Neurological Sciences, 2017, 38, 203-205.	0.9	1
105	RTD-fluxgate sensor for measurements of metal compounds in neurodegenerative diseases. , 2017, , .		3
106	Iron and Parkinson's disease: A systematic review and meta-analysis. Molecular Medicine Reports, 2017, 15, 3383-3389.	1.1	27
107	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	1.1	32
108	Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. PLoS ONE, 2017, 12, e0172145.	1.1	21

#	Article	IF	CITATIONS
109	A screening questionnaire for convulsive seizures: A three-stage field-validation in rural Bolivia. PLoS ONE, 2017, 12, e0173945.	1.1	18
110	Neurotoxocariais: A Rare or Neglected Disease?. Journal of Neuroinfectious Diseases, 2016, 07, .	0.2	0
111	Benign form of myasthenia gravis after nivolumab treatment. Muscle and Nerve, 2016, 54, 507-509.	1.0	40
112	Toe pseudoathetosis in vitamin B12 deficiency. European Journal of Neurology, 2016, 23, e30-e31.	1.7	2
113	Seated Man Walking: A Provocation Maneuver for Parkinsonian Tremor. Movement Disorders Clinical Practice, 2016, 3, 212-213.	0.8	2
114	A case of severe leg oedema in a patient with Parkinson's disease treated with pramipexole. Postgraduate Medical Journal, 2016, 92, 484-484.	0.9	3
115	Validation of the UPDRS section IV for detection of motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 27, 98-101.	1.1	13
116	Is it just a coincidence? Three new cases of Myasthenia Gravis associated with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 28, 166-168.	1.1	6
117	Response to the letter: "Obsessive compulsive personality disorder in Progressive Supranuclear Palsy― by Golimstok. Parkinsonism and Related Disorders, 2016, 33, 144-145.	1.1	0
118	Risk factors in multiple sclerosis: a population-based case–control study in Sicily. Background and methods. Neurological Sciences, 2016, 37, 1931-1937.	0.9	13
119	Obsessive compulsive personality disorder in Progressive Supranuclear Palsy, Multiple System Atrophy and Essential Tremor. Parkinsonism and Related Disorders, 2016, 30, 36-39.	1.1	9
120	Pregabalin for essential tremor. The Cochrane Library, 2016, 10, CD009682.	1.5	4
121	Extensive bilateral striopallidodentate calcinosis: a 50Âyears history of hypoparathyroidism presenting like a parkinsonian syndrome. Journal of Neurology, 2016, 263, 1876-1879.	1.8	6
122	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. European Journal of Neurology, 2016, 23, 964-972.	1.7	34
123	Comment on â€~A photoelectron spectroscopy study of lava stones' by D. A. Cristaldi, C. G. Fortuna and A. Gulino, Anal. Methods, 2013, 5 , 3458. Analytical Methods, 2016, 8, 3847-3848.	1.3	0
124	Effect of botulinum toxin treatment on quality of life in patients with isolated lingual dystonia and oromandibular dystonia affecting the tongue. Journal of Neurology, 2016, 263, 1702-1708.	1.8	35
125	A multisensor approach to perform instrumented postural instability tests for patient with Parkinson disease. , $2016, , .$		3
126	Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism. Neurological Sciences, 2016, 37, 591-595.	0.9	31

#	Article	IF	Citations
127	Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease. Journal of Neurology, 2016, 263, 888-894.	1.8	29
128	Tremor pattern differentiates drug-induced resting tremor from Parkinson disease. Parkinsonism and Related Disorders, 2016, 25, 100-103.	1.1	17
129	Looks can be deceiving: three cases of neurological diseases mimicking Guillain–BarrÔ syndrome. Neurological Sciences, 2016, 37, 541-545.	0.9	7
130	A scoping review of cost-effectiveness of screening and treatment for latent tuberculosis infection in migrants from high-incidence countries. BMC Health Services Research, 2015, 15, 412.	0.9	53
131	A Case of Apraxic Agraphia in a Patient With Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2015, 2, 308-309.	0.8	1
132	Coffee consumption and risk of levodopaâ€induced dyskinesia in Parkinson's disease: The FRAGAMP study. Movement Disorders, 2015, 30, 1854-1856.	2.2	16
133	Prevalence and Incidence of Epilepsy Associated with Convulsive Seizures in Rural Bolivia. A Global Campaign against Epilepsy Project. PLoS ONE, 2015, 10, e0139108.	1.1	17
134	Obsessive–compulsive personality disorder in drug-naìve Parkinson's disease patients. Journal of Neurology, 2015, 262, 485-486.	1.8	13
135	Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily. Journal of Neurology, 2015, 262, 923-930.	1.8	46
136	Electroencephalographic lateralization, clinical correlates and pharmacological response in untreated Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 948-953.	1.1	14
137	Prevalence of strongyloidiasis in Latin America: a systematic review of the literature. Epidemiology and Infection, 2015, 143, 452-460.	1.0	64
138	Pisa syndrome in Parkinson disease. Neurology, 2015, 85, 1769-1779.	1.5	72
139	Restless legs syndrome and multiple sclerosis: a population based caseâ^'control study in Catania, Sicily. European Journal of Neurology, 2015, 22, 1018-1021.	1.7	25
140	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Frontiers in Cellular Neuroscience, 2014, 8, 156.	1.8	150
141	High prevalence of clustered tuberculosis cases in Peruvian migrants in Florence, Italy. Gastroenterology Insights, 2014, 6, 5646.	0.7	5
142	Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurological Sciences, 2014, 35, 1173-1180.	0.9	80
143	Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. Schizophrenia Research, 2014, 152, 344-349.	1.1	38
144	Validation of the Italian version of the Movement Disorder Society—Unified Parkinson's Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	0.9	123

#	Article	IF	CITATIONS
145	Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology, 2013, 260, 714-740.	1.8	74
146	Sacsin-Related Spastic Ataxia Caused by a Novel Missense Mutation p.Arg272His in a Patient from Sicily, Southern Italy. Cerebellum, 2013, 12, 589-592.	1.4	3
147	Cognitive impairment and "invisible symptoms―are not associated with CCSVI in MS. BMC Neurology, 2013, 13, 97.	0.8	6
148	Clinical diagnostic tricks for detecting psychogenic gaze paralysis. European Journal of Neurology, 2013, 20, e107-8.	1.7	5
149	Subacute combined degeneration of the spinal cord presenting with pseudoathetosis of the upper limbs. European Journal of Neurology, 2013, 20, e26-7.	1.7	6
150	Epilepsy and Neurocysticercosis in Latin America: A Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2013, 7, e2480.	1.3	110
151	Toxocariasis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 114, 217-228.	1.0	44
152	Obsessive Compulsive Personality Disorder and Parkinson's Disease. PLoS ONE, 2013, 8, e54822.	1.1	28
153	Multiple Sclerosis in the Mount Etna Region: Possible Role of Volcanogenic Trace Elements. PLoS ONE, 2013, 8, e74259.	1.1	17
154	Epidemiology and Management of Cysticercosis and Taenia solium Taeniasis in Europe, Systematic Review 1990–2011. PLoS ONE, 2013, 8, e69537.	1.1	85
155	Toxocariasis and Epilepsy: Systematic Review and Meta-Analysis. PLoS Neglected Tropical Diseases, 2012, 6, e1775.	1.3	120
156	Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 76-82.	0.9	82
157	The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. Journal of Neurology, 2012, 259, 2621-2631.	1.8	188
158	Amplitude fluctuations in essential tremor. Parkinsonism and Related Disorders, 2012, 18, 859-863.	1.1	36
159	[1231]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. Schizophrenia Research, 2012, 139, 40-45.	1.1	32
160	Epilepsy-associated stigma in Bolivia: A communityâ€based study among the Guarani population. Epilepsy and Behavior, 2012, 25, 131-136.	0.9	27
161	Multiple Sclerosis and CCSVI: A Population-Based Case Control Study. PLoS ONE, 2012, 7, e41227.	1.1	25
162	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. Neurological Sciences, 2012, 33, 585-593.	0.9	18

#	Article	IF	CITATIONS
163	Frequency and severity of headache is worsened by Interferon- \hat{l}^2 therapy in patients with multiple sclerosis. Acta Neurologica Scandinavica, 2012, 125, 91-95.	1.0	38
164	[123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. Acta Neurologica Scandinavica, 2012, 126, 12-16.	1.0	44
165	Parkinson's disease is associated with increased serum levels of macrophage migration inhibitory factor. Cytokine, 2011, 55, 165-167.	1.4	41
166	Sociocultural dimension of epilepsy: An anthropological study among GuaranÃ-communities in Bolivia—An International League Against Epilepsy/International Bureau for Epilepsy/World Health Organization Global Campaign Against Epilepsy Regional Project. Epilepsy and Behavior, 2011, 22, 346-351.	0.9	17
167	Association study between the LINGO1 gene and Parkinson's disease in the Italian population. Parkinsonism and Related Disorders, 2011, 17, 638-641.	1.1	13
168	Single Photon Emission Computed Tomography Striatal Asymmetry Index May Predict Dopaminergic Responsiveness in Parkinson Disease. Clinical Neuropharmacology, 2011, 34, 71-73.	0.2	24
169	Presenilin-2 gene mutation presenting as Lewy Body dementia?. Neurological Sciences, 2011, 32, 533-534.	0.9	9
170	Putaminal, but not nigral alterations, characterize hemiparkinsonism-hemiatrophy syndrome: A case report. Movement Disorders, 2011, 26, 352-354.	2.2	5
171	Wine drinking and essential tremor: A possible protective role. Movement Disorders, 2011, 26, 1310-1315.	2.2	8
172	Reproductive factors and Parkinson's disease: A multicenter case–control study. Movement Disorders, 2011, 26, 2563-2566.	2.2	31
173	Increasing frequency of multiple sclerosis in Catania, Sicily: a 30-year survey. Multiple Sclerosis Journal, 2011, 17, 273-280.	1.4	36
174	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. Journal of Neurology, 2010, 257, 5-14.	1.8	140
175	The role of the long-duration response to levodopa in Parkinson's disease. Journal of Neurology, 2010, 257, 284-287.	1.8	4
176	The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. Neurological Sciences, 2010, 31, 47-52.	0.9	15
177	Voluptuary habits and clinical subtypes of Parkinson's disease: The FRAGAMP case–control study. Movement Disorders, 2010, 25, 2387-2394.	2.2	35
178	Metaâ€analysis of the association between cysticercosis and epilepsy in Africa. Epilepsia, 2010, 51, 830-837.	2.6	73
179	Toxocariasis. Epilepsies, 2010, 22, 120-125.	0.0	3
180	Multiple sclerosis and solar exposure before the age of 15 years: caseâ€"control study in Cuba, Martinique and Sicily. Multiple Sclerosis Journal, 2010, 16, 899-908.	1.4	33

#	Article	IF	CITATIONS
181	Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Multiple Sclerosis Journal, 2010, 16, 742-748.	1.4	63
182	Lack of interaction between LRP1 and A2M polymorphisms for the risk of Alzheimer disease. Neuroscience Letters, 2010, 482, 112-116.	1.0	20
183	International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology, 2009, 73, 1584-1591.	1.5	213
184	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily: an update. Multiple Sclerosis Journal, 2009, 15, 129-130.	1.4	9
185	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement Disorders, 2009, 24, 1641-1649.	2.2	1,171
186	Natural history and mortality of chronic epilepsy in an untreated population of rural Bolivia: A followâ€up after 10 years. Epilepsia, 2009, 50, 2199-2206.	2.6	75
187	Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clinical and Experimental Immunology, 2009, 159, 159-168.	1.1	26
188	Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?. Journal of Neurology, 2008, 255, 1250-1253.	1.8	74
189	Epilepsy and toxocariasis: a case–control study in Italy. Epilepsia, 2008, 49, 594-599.	2.6	60
190	Headache and Multiple Sclerosis: A Population-Based Case-Control Study in Catania, Sicily. Cephalalgia, 2008, 28, 1163-1169.	1.8	64
191	Comment on "Epilepsy and seropositivity rates of Toxocara canis and Toxoplasma gondii― Seizure: the Journal of the British Epilepsy Association, 2008, 17, 296.	0.9	5
192	Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. Parkinsonism and Related Disorders, 2008, 14, 572-575.	1.1	13
193	Prevalence of celiac disease in adult patients with refractory functional dyspepsia: Value of routine duodenal biopsy. World Journal of Gastroenterology, 2008, 14, 6948.	1.4	36
194	Frequency of celiac disease is not increased among multiple sclerosis patients. Multiple Sclerosis Journal, 2008, 14, 698-700.	1.4	26
195	Hormonal Replacement Therapy in Women With Parkinson Disease and Levodopa-Induced Dyskinesia. Clinical Neuropharmacology, 2007, 30, 276-280.	0.2	41
196	Depression and Quality of Life in Living Related Renal Transplantation. Transplantation Proceedings, 2007, 39, 1791-1793.	0.3	60
197	Epilepsy and Toxocariasis: A Case-Control Study in Burundi. Epilepsia, 2007, 48, 894-899.	2.6	69
198	Dissociation between motor and cognitive impairments in SCA2: Evidence from a follow-up study. Journal of Neurology, 2007, 254, 1455-1456.	1.8	24

#	Article	IF	CITATIONS
199	Evaluation of immunodiagnostics for toxocarosis in experimental porcine cysticercosis. Tropical Medicine and International Health, 2006, 12, 061109085615001-???.	1.0	5
200	Epilepsy and Neurocysticercosis in Rural Bolivia: A Population-based Survey. Epilepsia, 2005, 46, 1127-1132.	2.6	69
201	A possible spatial and temporal cluster of multiple sclerosis in the town of Linguaglossa, Sicily. Journal of Neurology, 2005, 252, 921-925.	1.8	20
202	The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing–remitting multiple sclerosis patients. Journal of Neurology, 2005, 252, 1255-1261.	1.8	30
203	Possible increasing risk of multiple sclerosis in Catania, Sicily. Neurology, 2005, 65, 1259-1263.	1.5	46
204	Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Journal of Neurology, 2004, 251, 1502-1506.	1.8	30
205	A screening instrument for a Sicilian neuroepidemiological survey in the elderly. Archives of Gerontology and Geriatrics, 2004, 38, 37-44.	1.4	6
206	Epilepsy and Multiple Sclerosis in Sicily: A Population-based Study. Epilepsia, 2003, 44, 1445-1448.	2.6	48
207	Prevalence of Parkinson's disease: a door-to-door survey in rural Bolivia. Parkinsonism and Related Disorders, 2003, 10, 19-21.	1.1	34
208	Lifetime Prevalence of Bell's Palsy in Rural Bolivia: A Door-to-Door Survey. Neuroepidemiology, 2002, 21, 100-104.	1.1	9
209	Epilepsy, cysticercosis, and toxocariasis. Neurology, 2002, 58, 1256-1261.	1.5	97
210	Cognitive findings in spinocerebellar ataxia type 2: relationship to genetic and clinical variables. Journal of the Neurological Sciences, 2002, 201, 53-57.	0.3	60
211	Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology, 2001, 57, 342-344.	1.5	86
212	Prevalence and incidence of multiple sclerosis in Catania, Sicily. Neurology, 2001, 56, 62-66.	1.5	60
213	Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 404-407.	0.9	49
214	Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Multiple Sclerosis Journal, 2001, 7, 101-104.	1.4	8
215	Prevalence of Stroke. Stroke, 2000, 31, 882-885.	1.0	62
216	Isolated, unilateral, reversible palsy of the hypoglossal nerve. European Journal of Neurology, 2000, 7, 347-349.	1.7	31

#	Article	IF	CITATIONS
217	Is season of birth associated with multiple sclerosis?. Acta Neurologica Scandinavica, 2000, 101, 381-383.	1.0	36
218	The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon- \hat{l}^2 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells. Autoimmunity, 2000, 32, 265-270.	1.2	4
219	SHORT-TERM TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS WITH INTERFERON (IFN)-β1B TRANSIENTLY INCREASES THE BLOOD LEVELS OF INTERLEUKIN (IL)-6, IL-10 AND IFN-γ WITHOUT SIGNIFICANTLY MODIFYING THOSE OF IL-1β, IL-2, IL-4 AND TUMOUR NECROSIS FACTOR-α. Cytokine, 2000, 12, 682-687.	1.4	32
220	Letter to the Editor. Multiple Sclerosis Journal, 1999, 5, 377-377.	1.4	3
221	Prevalence of epilepsy in rural Bolivia. Neurology, 1999, 53, 2064-2064.	1.5	102
222	Clinical and molecular analysis of 11 Sicilian SCA2 families: influence of gender on age at onset. European Journal of Neurology, 1999, 6, 301-307.	1.7	31
223	Identification of SCA2 mutation in cases of spinocerebellar ataxia with no family history in mid-eastern Sicily. Italian Journal of Neurological Sciences, 1999, 20, 217-221.	0.1	5
224	Sodium fusidate in steroid resistant relapses of multiple sclerosis. Multiple Sclerosis Journal, 1999, 5, 377-377.	1.4	6
225	Blood levels of transforming growth factor-beta 1 (TGF- \hat{l}^2 1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN- \hat{l}^2 1b). Clinical and Experimental Immunology, 1998, 113, 96-99.	1.1	72
226	Sodium fusidate in Guillain-Barre syndrome: a case report. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 266-268.	0.9	13
227	A Neuroepidemiological Survey in Rural Bolivia: Background and Methods. Neuroepidemiology, 1998, 17, 273-280.	1.1	31
228	Seroprevalence of Toxocara canis-IgG antibodies in two rural Bolivian communities. Parassitologia, 1998, 40, 473-5.	0.5	15
229	Primary Neurosarcoidosis. The Neuroradiology Journal, 1997, 10, 103-106.	0.1	O
230	CIRCULATING SERUM LEVELS OF IL- 1 ra IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS ARE NORMAL DURING REMISSION PHASES BUT SIGNIFICANTLY INCREASED EITHER DURING EXACERBATIONS OR IN RESPONSE TO IFN- $\hat{1}^2$ TREATMENT. Cytokine, 1996, 8, 395-400.	1.4	81
231	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. Journal of Neuroimmunology, 1996, 70, 87-90.	1.1	112
232	High-level aminoglycoside resistance among enterococci isolated from blood cultures. Journal of Antimicrobial Chemotherapy, 1992, 29, 729-731.	1.3	13
233	Microbiological Considerations of the Etiological Agents of Lower Respiratory Tract Infections. Journal of Chemotherapy, 1992, 4, 211-215.	0.7	7
234	Preliminary evaluation of immunoadjuvant activity of an orally administered glucan extracted from Candida albicans. Arzneimittelforschung, 1992, 42, 1246-50.	0.5	6

#	Article	lF	CITATIONS
235	Morphometric magnetic resonance imaging corticoâ€subcortical features in Parkinson's disease with mild cognitive impairment. European Journal of Neurology, 0, , .	1.7	O